Skip to main content

Genetic and In Vitro Inhibition of and Calcific Aortic Valve Stenosis.

JACC. Basic to translational science

Authors: Nicolas Perrot, Vincenza Valerio, Donato Moschetta, S Matthijs Boekholdt, Christian Dina, Hao Yu Chen, Erik Abner, Andreas Martinsson, Hasanga D Manikpurage, Sidwell Rigade, Romain Capoulade, Elvira Mass, Marie-Annick Clavel, Thierry Le Tourneau, David Messika-Zeitoun, Nicholas J Wareham, James C Engert, Gianluca Polvani, Philippe Pibarot, Tõnu Esko, J Gustav Smith, Patrick Mathieu, George Thanassoulis, Jean-Jacques Schott, Yohan Bossé, Marina Camera, Sébastien Thériault, Paolo Poggio, Benoit J Arsenault

The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.

© 2020 The Authors.

PMID: 32760854

Participating cluster members